J. B. has been a consultant to/member of advisory board of and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Novartis, Roche, and Servier in the last 3 years. He is not an employee or stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. He currently receives funding from the European Union's Seventh Framework Programme to investigate the safety of risperidone in children (PERS), the long-term safety of methylphenidate (ADDUCE) and EU-AIMS to identify new treatment targets for ASD.
The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries
Article first published online: 3 JUN 2014
© 2014 International Society for Autism Research, Wiley Periodicals, Inc.
Volume 7, Issue 5, pages 543–554, October 2014
How to Cite
Wong, A. Y.S., Hsia, Y., Chan, E. W., Murphy, D. G.M., Simonoff, E., Buitelaar, J. K. and Wong, I. C.K. (2014), The Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries. Autism Res, 7: 543–554. doi: 10.1002/aur.1391
I. W. has received research funding and honoraria from various pharmaceutical companies, including Shire, Janssen-Cilag, and Bristol-Myers Squibb. He currently receives funding from the European Union's Seventh Framework Programme to investigate the safety of risperidone in children (PERS) and the long-term safety of methylphenidate (ADDUCE). He is also a director of Healthcare Innovation Technology Service Limited, which received funding from the IMI for taking part in the EU-AIMS project.
Conflict of interest: E. S., Y. H., E. W. C., and A. W. have no conflict of interest. D. G. M. has received research funding and honoraria from various pharmaceutical companies, including Shire and Janssen-Cilag, and has previously received honoraria from Janssen-Cilag and Wyeth. He is currently receiving funding from the IMI for EU-AIMS to identify new treatment targets for ASD.
- Issue published online: 16 OCT 2014
- Article first published online: 3 JUN 2014
- Manuscript Accepted: 21 APR 2014
- Manuscript Received: 21 SEP 2013
- Innovative Medicines Initiative (IMI). Grant Number: 115300
- European Union's Seventh Framework Programme. Grant Number: FP7/2007-2013
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- National Institute of Health Research (UK)
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!